Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 positive allosteric modulator.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise, with potential best-in-class pharmacology.
- No convulsions were observed in pre-clinical studies conducted in multiple species, including rabbits.
- Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company redefining neuroscience drug development.
No additional information is available at this time.
Author's summary: Neumora starts Phase 1 study of NMRA-898.
More News
- Renters’ Rights Bill does not protect tenants only council budgets warns expert
- OPPO, Ballet Philippines to promote Filipino Artistry with new partnership
- Let me explain why I think Star Trek: Enterprise is set in J.J. Abrams' Kelvin Timeline
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Older Patients and Women Bear the Brunt of CTD-ILD Burden
- Lululemon to sell NFL apparel in Fanatics deal
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- Sara Davies' DIY spooky sweet treats are perfect for this week's Halloween celebrations
- Telos Corporation to Announce Third Quarter 2025 Financial Results on November 10, 2025
- Logistics Horizon Scanner: October 2025